HighTower Advisors’s Ionis Pharmaceuticals IONS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $285K | Sell |
3,797
-1,325
| -26% | -$105K | ﹤0.01% | 3220 |
|
|
2025
Q4 | $405K | Sell |
5,122
-336
| -6% | -$25.3K | ﹤0.01% | 2798 |
|
|
2025
Q3 | $357K | Buy |
5,458
+101
| +2% | +$4.93K | ﹤0.01% | 2893 |
|
|
2025
Q2 | $212K | Buy |
+5,357
| New | +$175K | ﹤0.01% | 3228 |
|
|
2024
Q4 | – | Sell |
-5,559
| Closed | -$223K | – | 3937 |
|
|
2024
Q3 | $223K | Sell |
5,559
-75
| -1% | -$3.49K | ﹤0.01% | 3058 |
|
|
2024
Q2 | $271K | Buy |
5,634
+549
| +11% | +$22.5K | ﹤0.01% | 2802 |
|
|
2024
Q1 | $221K | Sell |
5,085
-6,001
| -54% | -$286K | ﹤0.01% | 2930 |
|
|
2023
Q4 | $560K | Sell |
11,086
-18
| -0.2% | -$862 | ﹤0.01% | 2237 |
|
|
2023
Q3 | $506K | Sell |
11,104
-145
| -1% | -$5.98K | ﹤0.01% | 2228 |
|
|
2023
Q2 | $461K | Sell |
11,249
-220
| -2% | -$8.45K | ﹤0.01% | 2258 |
|
|
2023
Q1 | $409K | Buy |
11,469
+303
| +3% | +$11.4K | ﹤0.01% | 2241 |
|
|
2022
Q4 | $421K | Buy |
11,166
+2,301
| +26% | +$96.8K | ﹤0.01% | 2244 |
|
|
2022
Q3 | $393K | Sell |
8,865
-623
| -7% | -$26.3K | ﹤0.01% | 2182 |
|
|
2022
Q2 | $349K | Buy |
9,488
+376
| +4% | +$14.2K | ﹤0.01% | 2262 |
|
|
2022
Q1 | $336K | Sell |
9,112
-18,026
| -66% | -$590K | ﹤0.01% | 2438 |
|
|
2021
Q4 | $826K | Buy |
27,138
+17,281
| +175% | +$544K | ﹤0.01% | 1861 |
|
|
2021
Q3 | $334K | Buy |
9,857
+554
| +6% | +$20.9K | ﹤0.01% | 2346 |
|
|
2021
Q2 | $366K | Sell |
9,303
-216
| -2% | -$8.46K | ﹤0.01% | 2238 |
|
|
2021
Q1 | $426K | Sell |
9,519
-5,563
| -37% | -$310K | ﹤0.01% | 2081 |
|
|
2020
Q4 | $854K | Buy |
15,082
+3,120
| +26% | +$155K | ﹤0.01% | 1351 |
|
|
2020
Q3 | $564K | Sell |
11,962
-76
| -0.6% | -$4.22K | ﹤0.01% | 1516 |
|
|
2020
Q2 | $703K | Sell |
12,038
-140
| -1% | -$7.79K | ﹤0.01% | 1287 |
|
|
2020
Q1 | $570K | Buy |
12,178
+289
| +2% | +$16.1K | ﹤0.01% | 1279 |
|
|
2019
Q4 | $717K | Sell |
11,889
-117
| -1% | -$6.97K | ﹤0.01% | 1280 |
|
|
2019
Q3 | $715K | Sell |
12,006
-197
| -2% | -$12.8K | ﹤0.01% | 1344 |
|
|
2019
Q2 | $789K | Buy |
12,203
+3,380
| +38% | +$239K | ﹤0.01% | 1312 |
|
|
2019
Q1 | $715K | Sell |
8,823
-10,054
| -53% | -$649K | ﹤0.01% | 1282 |
|
|
2018
Q4 | $1.02M | Buy |
18,877
+10,245
| +119% | +$523K | 0.01% | 1031 |
|
|
2018
Q3 | $449K | Sell |
8,632
-139
| -2% | -$6.53K | ﹤0.01% | 1511 |
|
|
2018
Q2 | $371K | Sell |
8,771
-748
| -8% | -$33.2K | ﹤0.01% | 1588 |
|
|
2018
Q1 | $421K | Sell |
9,519
-451
| -5% | -$22.9K | ﹤0.01% | 1507 |
|
|
2017
Q4 | $506K | Sell |
9,970
-690
| -6% | -$37.8K | ﹤0.01% | 1445 |
|
|
2017
Q3 | $545K | Buy |
10,660
+1,001
| +10% | +$52.4K | ﹤0.01% | 1391 |
|
|
2017
Q2 | $496K | Sell |
9,659
-1,580
| -14% | -$73.6K | ﹤0.01% | 1364 |
|
|
2017
Q1 | $449K | Buy |
11,239
+3,076
| +38% | +$138K | ﹤0.01% | 1374 |
|
|
2016
Q4 | $392K | Sell |
8,163
-5,906
| -42% | -$234K | ﹤0.01% | 1357 |
|
|
2016
Q3 | $511K | Buy |
+14,069
| New | +$440K | 0.01% | 1238 |
|
|
2016
Q2 | – | Sell |
-23,718
| Closed | -$954K | – | 1897 |
|
|
2016
Q1 | $954K | Buy |
23,718
+1,589
| +7% | +$64.5K | ﹤0.01% | 1058 |
|
|
2015
Q4 | $1.37M | Buy |
22,129
+15,702
| +244% | +$847K | 0.02% | 798 |
|
|
2015
Q3 | $256K | Buy |
6,427
+2,451
| +62% | +$127K | ﹤0.01% | 1533 |
|
|
2015
Q2 | $228K | Buy |
+3,976
| New | +$253K | ﹤0.01% | 1302 |
|
Other funds holding IONS
VPM
VCM
HighTower Advisors's IONS Position: Q1 2026 in Review
HighTower Advisors reduced its Ionis Pharmaceuticals (IONS) stake by 26% in Q1 2026, selling an estimated $105K and leaving 3,797 shares worth $285K. The position accounts for ﹤0.01% of the portfolio, ranked #3220.
HighTower Advisors first reported a position in IONS in Q2 2015 and has held it in 41 quarters since. The position peaked at $1.37M in Q4 2015. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.
- HighTower Advisors held 3,797 shares of Ionis Pharmaceuticals worth $285K as of Q1 2026.
- HighTower Advisors sold 1,325 Ionis Pharmaceuticals shares in Q1 2026, an estimated $105K.
- Ionis Pharmaceuticals made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #3220 holding.
- HighTower Advisors first reported a position in Ionis Pharmaceuticals in Q2 2015 and has held it in 41 quarters since.
- HighTower Advisors's Ionis Pharmaceuticals position peaked at $1.37M in Q4 2015.
- 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.
Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.